HDAC inhibitors: Clinical update and mechanism-based potential

Biochemical Pharmacology

Volumn 74, Issue 5, 2007, Pages 659-671

  Glaser, Keith B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Belinostat; Chromatin modification; Epigenetic regulation; Histone deacetylase inhibitors; LBH589; MGCD0103; MS 275; Romidepsin; Vorinostat

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BORTEZOMIB; CARBOPLATIN; DEPSIPEPTIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; FR 901228; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; ISOTRETINOIN; LBH 589; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXALIPLATIN; PACLITAXEL; RITUXIMAB; ROMIDEPSIN; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACETYLATION; ANOREXIA; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DNA METHYLATION; DNA REPAIR; DRUG HALF LIFE; DRUG INHIBITION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; GENE CONTROL; GENE MUTATION; GENE REPRESSION; GLIOMA; GROWTH INHIBITION; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; IN VITRO STUDY; LEUKEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PHLEBITIS; PLEURA CANCER; PRIORITY JOURNAL; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; VOMITING;

EID: 34547122494     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.007     Document Type: Note

References (85)

1. Taunton J., Hassig C.A., and Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272 5260 (1996) 408-411
2. Glaser K., Li J., Aakre M., Morgan D., Sheppard G., Stewart K., et al. Transforming growth factor β mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Mol Cancer Ther 1 (2002) 759-768
3. Su G., Sohn T., Rhyu B., and Kern S. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60 (2000) 3137-3142
4. Sohn T., Su G., Ryu B., Yeo C., and Kern S. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann Surg 233 5 (2001) 696-703
5. Nakajima H., Kim Y., Terano H., Yoshida M., and Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241 (1998) 126-133
6. Masuoka Y., Nagai A., Shin-ya K., Furihata K., Nagai K., Suzuki K.-i., et al. Spiruchostatin A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tet Lett 42 (2001) 41-44
7. Masuoka Y., Shin-Ya K., Furihata K., Hayakawa Y., and Seto H. A novel substance with TGF-β like activity, diheteropeptin, produced by a fungus, Diheterospora sp. J Antibiot 50 12 (1997) 1058-1060
8. Bolden J., Peart M., and Johnstone R. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
9. Rosato R., and Grant S. Histone deacetylase inhibitors in clinical development. Exp Opin Investig Drugs 13 1 (2004) 21-38
10. Rosato R., and Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Exp Opin Ther Targets 9 4 (2005) 809-824
11. Minucci S., and Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
12. Masuoka Y., Shin-Ya K., Kim Y.-B., Yoshida M., Nagi K., and Suzuki K.-I. Diheteropeptin, a novel substance with TGF-β activity, produced by a fungus Diheterospora chlamydosporia. J Antibiot 53 8 (2000) 788-792
13. Ng H., and Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci 25 (2000) 121-126
14. Bernstein B., Tong T., and Schreiber S. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci (USA) 97 25 (2000) 13708-13713
15. Glaser K., Li J., Staver M., Wei R.-Q., Albert D., and Davidsen S. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310 (2003) 529-536
16. Li J., Staver M., Curtin M., Holms J., Frey R., Edalji R., et al. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci 74 22 (2004) 2693-2705
17. Curtin M., and Glaser K. Histone deacetylase inhibitors: the Abbott experience. Curr Med Chem 10 (2003) 1241-1253
18. Glaser K.B., Li J., Staver M.J., Wei R.Q., Albert D.H., and Davidsen S.K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310 2 (2003) 529-536
19. Zhang C., Richon V., Ni X., Talpur R., and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125 (2005) 1045-1052
20. Piekarz R.L., Robey R.W., Zhan Z., Kayastha G., Sayah A., Abdeldaim A.H., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103 12 (2004) 4636-4643
21. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 1 (2007) 31-39
22. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 1 (2006) 166-173
23. Drummond D., Noble C., Kirpotin D., Guo Z., Scott G., and Benz C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45 (2005) 495-528
24. Duvic M., Kim Y., Kuzel T., Pacheco T., Foss F., Parker S., et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) provides clinical benefit to advanced cutaneous T-cell lymphoma patients: updated results of the phase IIb multicenter clinical trial. Blood 108 11 (2006) [Abstr# 399]
25. Konstantinopoulos P.A., Vandoros G.P., and Papavassiliou A.G. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 58 5 (2006) 711-715
26. Furumai R., Matsuyama A., Kobashi N., Lee K.-H., Nishiyama M., Nakajima H., et al. FK228(depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62 (2002) 4916-4921
27. Glaser K.B., Li J., Pease L.J., Staver M.J., Marcotte P.A., Guo J., et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem Biophys Res Commun 325 3 (2004) 683-690
28. Tabe Y., Konopleva M., Contractor R., Munsell M., Schober W.D., Jin L., et al. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107 4 (2006) 1546-1554
29. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8 3 (2002) 718-728
30. Piekarz R., Robey R., Sandor V., Bakke S., Wilson W., Dahmoush L., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98 9 (2001) 2865-2868
31. Piekarz R., Frye R., Turner M., Wright J., Allen S., Kirschbaum M., et al. Phase II trial of romidepsin, FK228, in cutaneous and peripheral T-cell lymphoma: clinical activity and molecular markers. Blood 108 11 (2006) [Abstr# 2469]
32. Piekarz R., Fryer A., Wright J., Steinberg S., Liewehr D., Rosing D., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin Cancer Res 12 12 (2006) 3762-3773
33. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., and Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci (USA) 98 1 (2001) 87-92
34. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 13 (2003) 3637-3645
35. Belien A., De Schepper S., Floren W., Janssens B., Marien A., King P., et al. Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors. Mol Cancer Ther 5 9 (2006) 2317-2323
36. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23 17 (2005) 3912-3922
37. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2006)
38. Grant S. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?. Leukemia 18 12 (2004) 1931-1933
39. Yu X., Guo Z., Marcu M., Neckers L., Nguyen D., Chen G., et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94 7 (2002) 504-513
40. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive and -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63 (2003) 5126-5135
41. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deaceylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108 2 (2006) 645-652
42. Bali P., George P., Cohen P., Tao J., Guo F., Sigua C., et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT3. Clin Cancer Res 10 (2004) 4994-4997
43. Fiskus W., Herger B., Rao R., Atadja P., and Bhalla K. Hydroxamate pan-HDAC inhibitor LBH589 depletes EZH2 and DNMT1 partlty through Hsp90 inhibition and its chaperone association with DNMT1. Blood 108 11 (2006) [Abstr# 2233]
44. Prince M., George D., Johnstone R., McCormack C., Ellis L., Williams-Truax R., et al. LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin expression profiles in the first 24 h related to clinical response following therapy. Blood 108 11 (2006) [Abstr# 2715]
45. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2 8 (2003) 721-728
46. Plumb J., Steele N., Finn P., and Brown R. Epigenetic approaches to cancer therapy. Biochem Soc Trans 32 6 (2004) 1095-1097
47. Qian X., LaRochelle W.J., Ara G., Wu F., Petersen K.D., Thougaard A., et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5 8 (2006) 2086-2095
48. Tumber A., Collins L.S., Petersen K.D., Thougaard A., Christiansen S.J., Dejligbjerg M., et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60 (2007) 275-283
49. Hose C., Shoemaker R., and Monks A. Gene profiling of PXD-101, a novel hydroxamate type inhibitor of histone deacetylase, leads to identification of aurora kinase inhibition. AACR-EORTC-NCI molecular targets and cancer therapeutics conference (2005)
50. deBono J., Steele N., Vidal L., Plumb J., Attard G., Tjornlund J., et al. A phase 1 pharmacokinetic (PD) and pharmacodynamic (PD) study of the histone deacetylase inhibitor PXD101 in patients with advanced solid tumors. AACR-EORTC-NCI molecular targets and cancer therapeutics conference (2005) [Abstr# C88]
51. Northfelt D., Ooi C., Gerwien R., Hawthorne T., Clarke A., Jones S., et al. A phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors. 18th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics (2006) [Abstr# 181]
52. Sullivan D., Singhal S., Schuster M., Berenson J., Gimsing P., Wisloff F., et al. A phase II study of PXD101 in advanced multiple myeloma. Blood 108 11 (2006) [Abstr# 3583]
53. Lancet J., Nichols G., Assoulin S., Burton M., Mintz M., Green M., et al. A phase 1 study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS). Blood 108 11 (2006) [Abstr# 1971.5]
54. Warrell R., He L.-Z., Richon V., Calleja E., and Pandolfi P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90 21 (1998) 1621-1625
55. Zhou D.-C., Kim S., Ding W., Schultz C., Warrell R., and Gallagher R. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99 4 (2002) 1356-1363
56. Yang X., Ferguson A.T., Nass S.J., Phillips D.L., Butash K.A., Wang S.M., et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60 (2000) 6890-6894
57. Keen J., Yan L., and Mack K. A novel hisotne deacetylase inhibitor, scriptaid, enhances expression of estrogen receptor alpha (ER) in ER-negative human breast cancer cells in combination with 5-aza-2′-deoxycytidine. Breast Cancer Res Treat 81 (2003) 177-186
58. Zhou Q., Atadja P., and Davidson N. Hisotne deactylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of hypermethylation. Cancer Biol Ther 6 1 (2007) [Epub ahead of print]
59. Sharma D., Saxena N., Davidson N., and Vertino P. Restoration of tamoxifen sensitivity in estrogen-receptor negative breast cancer cells: tomoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66 12 (2006) 6370-6378
60. Reid G., Metivier R., Lin C.Y., Denger S., Ibberson D., Ivacevic T., et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24 31 (2005) 4894-4907
61. Munshi A., Tanaka T., Hobbs M., Tucker S., Richon V., and Meyn R. Vorinostat a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gama-H2AX foci. Molec Cancer Ther 5 8 (2006) 1967-1974
62. Kao G., McKenna W., Guenther M., Muschel R., Lazar M., and Yen T. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 160 7 (2003) 1017-1027
63. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 5 (2003) 330-338
64. Glaser K., Staver M., Waring J., Stender J., Ulrich R., and Davidsen S. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
65. Ocker M., Alajati A., Ganslmayer M., Zopf S., Luders M., Neureiter D., et al. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131 (2005) 385-394
66. Zhang X., Yashiro M., Ren J., and Hirakawa K. Histone deacetylase inhbitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16 (2006) 563-568
67. Berg R.W., Ferguso P.J., DeMoor J.M., Vincen M.D., and Koropatnick J. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger. Curr Drug Targets 3 4 (2002) 297-309
68. Matsuoka K., Tsukuda K., Suda M., Kobayashi K., Ota T., Okita A., et al. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil. Int J Oncol 24 1 (2004) 217-222
69. Lee J.-H., Park J.-H., Jung Y., Kim J.-H., Jong H.-S., Kim T.-Y., et al. Histone deactylase inhibitor enhances 5-fluorouracil cytotoxicity b down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 5 12 (2006) 3085-3095
70. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with Vorinostat (suberoylanilide hydroxamic acid) enhances activity of Dasatinib (BMS-354825) against Imatinib mesylate-sensitive and Imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 12 19 (2006) 5869-5878
71. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 6765 (2000) 41-45
72. Turner B.M. Histone acetylation and an epigenetic code. Bioessays 22 9 (2000) 836-845
73. Turner B. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Molec Biol 12 2 (2005) 110-112
74. Turner B.M. Defining an epigenetic code. Nat Cell Biol 9 1 (2007) 2-6
75. Esteller M. Epigenetics provides a new geneation of oncogenes and tumour-suppressor genes. Br J Cancer 94 (2006) 179-183
76. Huang J., Perez-Burgos L., Placek B., Sengupta R., Richter M., Dorsey J., et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444 (2006) 629-632
77. Shi Y., and Whetstine J.R. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 25 1 (2007) 1-14
78. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366 9485 (2005) 549-555
79. Ylisastigui L., Archin N.M., Lehrman G., Bosch R.J., and Margolis D.M. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18 8 (2004) 1101-1108
80. Brogdon J., Xu Y., Szabo S., An S., Buxton F., Cohen D., et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109 3 (2007) 1123-1130
81. Inoue K., Kobayashi M., Yano K., Miura M., Izumi A., Mataki C., et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Thromb Vasc Biol 26 12 (2006) 2652-2659
82. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., et al. Pharmacological inhibition of histone deacetylases (HDACs) by suberoylanilide hydroxamic acid (SAHA) specifically alters gene expression and reduces ischemic injury in the mouse brain. Molec Phramacol 70 6 (2006) 1876-1884
83. Butler R., and Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7 10 (2006) 784-796
84. Sadri-Vakili G., and Cha J.H. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res 3 4 (2006) 403-408
85. Haggarty S., Koeller K., Wong J., Grozinger C., and Schreiber S. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci (USA) 100 8 (2003) 4389-4394